StoxBiocon vs Gland Pharma: share price & financials comparison
NSE: BIOCON vs GLAND · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Biocon vs Gland Pharma at a glance
Biocon (BIOCON) has a market capitalisation of ₹59,497 Cr, against ₹52,281 Cr for Gland Pharma (GLAND). Over the past year Gland Pharma has returned +66.4%, compared with -2.3% for Biocon. On valuation, Gland Pharma trades at a lower P/E of 46.3 versus 131.6. Gland Pharma earns a higher return on equity (10.9% vs 1.3%). Gland Pharma comes out ahead on size, valuation, profitability, growth, financial health, momentum and technicals. Across the scored metrics below, Biocon leads on 4 and Gland Pharma on 13. On StoxGud's 10-point checklist, Biocon scores 3/10 and Gland Pharma scores 9/10.
| Metric | Biocon | Gland Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹59,497 Cr | ₹52,281 Cr |
| Revenue (latest FY) | ₹16,927 Cr | ₹6,431 Cr |
| Net profit (latest FY) | ₹386 Cr | ₹1,027 Cr |
| Valuation | ||
| P/E | 131.6 | 46.3 |
| P/B | 1.71 | 5.05 |
| Dividend yield | 0.15% | 0.57% |
| Profitability | ||
| Return on equity | 1.3% | 10.9% |
| Net profit margin | 2.6% | 16.8% |
| Operating margin | 20.3% | 26.0% |
| Growth | ||
| Revenue growth (YoY) | +2.2% | +19.6% |
| Net profit growth (YoY) | -51.1% | +47.1% |
| Revenue CAGR (multi-year) | +19.0% | +13.2% |
| Financial health | ||
| Debt to equity | 0.43 | 0.02 |
| Momentum | ||
| 1-month return | +1.4% | +0.6% |
| 1-year return | -2.3% | +66.4% |
| 3-year CAGR | +17.5% | +26.2% |
| 5-year CAGR | +0.9% | -2.8% |
| 10-year CAGR | +9.3% | — |
| Distance from 52W high | -17.2% | +0.0% |
| Technicals | ||
| RSI (14) | 59 | 60 |
| Price vs 200-day avg | -6.4% | +37.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Biocon | Gland Pharma |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 3/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Biocon or Gland Pharma?
Biocon has a market cap of ₹59,497 Cr and Gland Pharma has a market cap of ₹52,281 Cr as of 06 Nov 2026.
Which has a lower P/E, Biocon or Gland Pharma?
Gland Pharma has the lower P/E: Biocon trades at 131.6 and Gland Pharma at 46.3.
Which gave better returns in the last year, Biocon or Gland Pharma?
Gland Pharma did better: Biocon returned -2.3% and Gland Pharma returned +66.4% over one year.
Is Biocon or Gland Pharma a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Biocon scores 3/10 and Gland Pharma scores 9/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.